Bristols’ DLBCL CAR-T Therapy -Lisocabtagene Maraleucel (JCAR017) Future Strategy & Latest Events

Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover […]